Terumo Corporation has announced a €150 million agreement to acquire WuXi Biologics’ drug product (DP) manufacturing plant located in Leverkusen, Germany. The facility will serve as Terumo’s first overseas base for its contract development and manufacturing organisation (CDMO) business. The site
Terumo BCT and Charles River Laboratories have released data showcasing the adaptability of Terumo BCT’s Finia automated fill and finish system in various cell and gene therapy (CGT) workflows. The Finia platform, designed to optimize the cooling, aliquoting, and packaging
Terumo is a mid to large size-global medical device company based in Japan, with offices in over 160 countries around the world and over 50,000 products and services. The Terumo Pharmaceutical Solutions Division, also known as ‘PSD’, is a leading
Terumo Contract Manufacturing & Development (CDMO) Profile Currently, the Terumo Group includes three companies that operate in over 160 countries and regions around the world, providing patients, a variety of medical settings, and the pharmaceutical industry with over 50,000 products
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
